论文部分内容阅读
目的通过分析盐酸多奈哌齐所致不良反应(ADR),评价其安全性。方法采用回顾性方法,对医院2012年1月-2016年1月收集的35例应用盐酸多奈哌齐导致ADR的报告中患者的性别、年龄、发生ADR的时间、累及器官或系统等情况进行分类统计和分析。结果 35例ADR报告中,以年龄>70岁为主,女22例(62.86%),男13例(37.14%);患者发生ADR的时间多在用药15 d内占40.00%;ADR临床表现以消化系统反应为主,占42.86%,其中出现心动过缓、胸闷、心悸1例,肝功能指标异常1例。结论阿尔茨海默病(AD)或血管性痴呆(VD)患者多为老年患者,盐酸多奈哌齐作为首选药物,临床应用广泛,其用药安全性应引起足够重视,以促进临床合理用药。
Objective To evaluate the safety of donepezil hydrochloride by analyzing the adverse effects of donepezil hydrochloride (ADR). Methods A retrospective analysis was conducted on the gender, age, duration of ADR, organ involvement or systemic involvement of 35 patients with ADR reported by the hospital from January 2012 to January 2016 in the hospital. analysis. Results Among the 35 ADR cases, the age was more than 70 years, 22 (62.86%) were females and 13 (37.14%) were males. The ADR time was 40.00% within 15 days of treatment. The clinical manifestations of ADR Digestive system reaction, accounting for 42.86%, of which there was bradycardia, chest tightness, palpitations in 1 case, abnormal liver function in 1 case. Conclusion Most patients with Alzheimer’s disease (AD) or vascular dementia (VD) are elderly patients. Donepezil hydrochloride is the first choice of drug and has wide range of clinical applications. Its safety should be given enough attention to promote rational drug use in clinic.